TET2 and systemic mastocytosis: This approach paves the way for future treatment strategies for KIT D816V positive and TET2 mutation carrying SM patients, where pre-treatment with demethylating agents like DAC followed by TKIs like Dasatinib and Midostaurin may yield better therapeutic outcomes.